K_ATP-channel openers for the treatment of breast and endometrial cancer

Abstract

Frequently, hyperinsulinaemia is the result of obesity, lack of physical activity and a diet rich in carbohydrates, such as glucose or fructose. Chronic exposure to hyperinsulinaemia enhances the bioavailability of insulin-like growth factor-1 (IGF-1). A positive correlation has been demonstrated between high plasma concentration of IGF-1 and insulin and the risk of breast or endometrial cancer. In this patent application, Novo Nordisk claims the use of K_ATP-channel openers (KCOs) to reduce breast and endometrial cancer through a decrease of the insulin plasma level.

• cancer
• hyperinsulinaemia
• K_ATP-channel openers